- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04574713
Candesartan for Migraine Prevention: (CandMig-3)
April 4, 2024 updated by: St. Olavs Hospital
Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg)
The main objective of this study is to see whether the favorable preventative effect of candesartan 16 mg per day in episodic migraine, that was found previously in two smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study.
In addition it will be investigated whether 1) also a smaller dose of 8 mg is effective, and 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
450
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Erling Tronvik, md prof
- Phone Number: +47 40458528
- Email: erling.tronvik@ntnu.no
Study Contact Backup
- Name: Lise Rystad Øie, phd
- Email: lise.r.oie@ntnu.no
Study Locations
-
-
-
Tartu, Estonia
- Tartu University Clinics
-
-
-
-
-
Bergen, Norway
- Haukeland University Hospital
-
Bodø, Norway
- Nordland Hospital
-
Kristiansand, Norway
- Sørlandet Hospital
-
Lørenskog, Norway
- Akershus University Hospital AHUS
-
Molde, Norway
- Møre and Romsdal Hospital Molde
-
Oslo, Norway
- Ullevål University Hospital
-
Oslo, Norway
- Rikshospitalet University Hospital
-
Tromsø, Norway
- University Hospital of North Norway
-
Trondheim, Norway
- St Olavs Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed informed consent
- Episodic migraine with or without aura according to ICHD-3 criteria
- At inclusion, patients should retrospectively have from 2 to 8 migraine attacks per month during the last 3 months. This frequency must be confirmed in the headache diary before randomization to treatment.
- Debut of migraine at least one year prior to inclusion
- Start of migraine before age 50 years
- No use of other migraine prophylactics during the study
- For women of child-bearing potential, use of highly effective contraception.
Exclusion Criteria:
- Interval headache not distinguishable from migraine;
- Chronic migraine, chronic tension-type headache, medication overuse headache or other headache occurring on ≥ 15 days/month
- Pregnancy, planning to get pregnant, inability to use contraceptives, lactating
- Clinical information on or signs of cholestasis or decreased hepatic or renal function. If in doubt, relevant blood tests should be performed
- High degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator
- Hypersensitivity to candesartan
- History of angioneurotic oedema
- Current use of antihypertensive medication
- Current use of potassium supplements
- Current use of spironolactone
- Primary hyperaldosteronism (Conn's syndrome)
- Significant psychiatric illness
- Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study
- Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years
- Previous use of candesartan
- Requiring detoxification from acute medication (triptans, opioids)
- Consistently failing to respond to any acute migraine medication
- Alcohol or illicit drug dependence.
- Inability to understand study procedures and to comply with them for the entire length of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control group
|
1 over-encapsulated tablet once daily, containing placebo, for 12 weeks (84 days).
|
Experimental: Candesartan 8 mg
|
1 over-encapsulated tablet once daily, containing candesartan 8 mg, for 12 weeks (84 days).
|
Experimental: Candesartan 16 mg
|
1 over-encapsulated tablet once daily, containing candesartan 16 mg, for 12 weeks (84 days).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in number of migraine days per 4 weeks, from baseline
Time Frame: 20 weeks plus final visit 1 week after treatment
|
participants will fill in a headache diary during 20 weeks treatment
|
20 weeks plus final visit 1 week after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Christian Samsonsen, md phd, St Olavs Hospital, Dept Neurology & Clinical Neurophysiology
- Study Director: Jorunn L Helbostad, prof, Norwegian University of Science and Technology, Fac MH, Dept INB
- Principal Investigator: Erling Tronvik, md prof, Norwegian University of Science and Technology, Fac MH, Dept INB
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2020
Primary Completion (Estimated)
April 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
September 28, 2020
First Submitted That Met QC Criteria
October 2, 2020
First Posted (Actual)
October 5, 2020
Study Record Updates
Last Update Posted (Actual)
April 5, 2024
Last Update Submitted That Met QC Criteria
April 4, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Candesartan
- Candesartan cilexetil
Other Study ID Numbers
- 63527
- 2019-003386-18 (EudraCT Number)
- NFR 288699. (Other Grant/Funding Number: Research Council of Norway)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Candesartan Oral Tablet 8 mg
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Concert PharmaceuticalsCompleted
-
Pila PharmaCompletedDiabetes Mellitus, Type 2Denmark
-
Cassava Sciences, Inc.National Institute on Aging (NIA)Completed
-
Fulcrum TherapeuticsCompletedHealthy Adult SubjectsUnited States
-
Cara Therapeutics, Inc.RecruitingChronic Kidney Diseases | PruritusUnited States
-
Cara Therapeutics, Inc.RecruitingChronic Kidney Diseases | PruritusUnited States, Korea, Republic of, Australia, Bulgaria, Germany, Hungary, Italy, Poland, Romania, Spain, Argentina, Brazil, Mexico
-
University of MilanNot yet recruiting
-
Institut BergoniéNovartisTerminatedLeukemia, Myeloid, Chronic-PhaseFrance